Jubilant Pharmova arm receives ANDA approval for Doxepin Hydrochloride Capsules

Jubilant Pharmova Limited, an integrated global Pharmaceuticals Company, has announced that Jubilant Pharma Limited, a material wholly owned subsidiary of the Company, through one of its subsidiaries, Jubilant Cadista Pharmaceuticals Inc. has received Abbreviated New Drug Application (ANDA) final approval for Doxepin Hydrochloride Capsules, 10 mg, 25mg, 50mg, 75mg, and 100mg, the generic version of Sinequan®, which is used for the treatment of anxiety, depression, and other target symptoms of psychoneurosis.

As on December 31, 2021, Jubilant's Pharmaceuticals business had a total of 98 ANDAs for Oral Solids filed in the US, of which 61 have been approved and 4 Injectable / Opthalmic filings, of which 2 have been approved.

Shares of Jubilant Pharmova Limited was last trading in BSE at Rs. 407.55 as compared to the previous close of Rs. 405.65. The total number of shares traded during the day was 14441 in over 1108 trades.

The stock hit an intraday high of Rs. 418.90 and intraday low of 405.65. The net turnover during the day was Rs. 5951474.00.

Source : Equity Bulls

Keywords

JubilantPharmova INE700A01033 JubilantPharma JubilantCadistaPharmaceuticals ANDA Approval